Radiotherapy remains a mainstay of prostate cancer treatment.
Researchers in Los Angeles found that some men (i.e., those with low-risk prostate cancer or intermediate-risk prostate cancer) can be successfully treated using higher doses of radiation over less time. Meanwhile, researchers at Mount Sinai Hospital, also in the USA, have developed a ‘machine learning framework’, a clever way to automatically analyze data and make predictions based on that information, to help predict whether a prostate cancer is high- or low-risk. It’s thought that this innovation will particularly help radiologists decide how best to treat an individual’s cancer. A small research study in Australia has discovered that men with aggressive prostate cancer that has spread throughout the body generally lived about four months longer than average when given a new radiation-based treatment called LuPMSA. Because only a small number of men have been tested, and this is an early clinical trial, it’s too soon to be certain that this treatment will work or how good it is. However, it’s very encouraging that it has been successful up to this point, and we hope it leads to better treatment options for men with advanced disease.
Closer to home, the STAMPEDE trial unfortunately found that standard radiotherapy administered to the prostate does not seem to help men with newly diagnosed prostate cancer that has already spread throughout the body to live any longer. Find out about PCR’s STAMPEDE project below.